V

Velocity Clinical Research | Norfolk, NE

Research site

(Unclaimed)

Location

3400 W Norfolk Ave, Norfolk, Nebraska, United States of America

Site insights

Top conditions

Top treatments

RTA 901

Dotinurad

Xanthine

BIIB143

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout w...

Enrolling

Gout

Drug: Dotinurad

Other: Placebo

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Active, not recruiting

Epstein-Barr Virus Infection

Biological: Placebo

Biological: mRNA-1195.1

Efficacy and Safety of NVX-CoV2705 (COVID-19)

This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approx...

Active, not recruiting

COVID-19

Sars-CoV-2 Infection

Biological: NVX-CoV2705

Biological: Placebo

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy a...

Active, not recruiting

Norovirus Acute Gastroenteritis

Biological: mRNA-1405

Biological: mRNA-1403